Levocetirizine and Pregnancy: Risks & Safety Information

Levocetirizine (Xyzal) is a third-generation antihistamine (active enantiomer of cetirizine). Current data: no evidence of major teratogenicity, but human data limited. FDA Pregnancy Category B (animal studies no risk; no adequate human studies).

Safety Summary

  • Animal Studies: No teratogenicity at doses >> human therapeutic. Crosses placenta.
  • Human Data: Limited prospective reports (mostly cetirizine, which shares metabolism). No signal for major malformations, miscarriage, or adverse pregnancy outcomes in available cohorts.
  • Placental Transfer: Yes, but fetal exposure low.
  • Breastfeeding: Low milk transfer (cetirizine data); considered compatible (L2-L3). Monitor infant for drowsiness.

Clinical Guidance

  • First-Line for Allergic Rhinitis in Pregnancy: Intranasal corticosteroids (fluticasone, mometasone, budesonide) – minimal systemic absorption.
  • Oral Antihistamine Alternatives with More Data:
    • Loratadine (Claritin) – Category B, largest pregnancy registry, preferred.
    • Cetirizine (Zyrtec) – Category B, extensive post-marketing data, preferred.
    • Chlorpheniramine (first-gen) – Category B, long history, but sedating.
  • If Levocetirizine Needed: Benefit (severe symptoms uncontrolled by safer options) vs. theoretical risk. Shared decision-making with OB.
  • Dose: 5 mg daily; 2.5 mg if CrCl <30 mL/min.

Non-Drug Measures

  • Saline nasal irrigation (neti pot).
  • Allergen avoidance (encasings, HEPA, pet restrictions).
  • Nasal strips for congestion.

Always discuss medications with your prenatal provider. “Natural” ≠ safe (e.g., some herbal supplements contraindicated).

Pregnancy & Health - Related Articles